Heart failure & cardiomyopathiesCohort study
Safety and Prognostic Value of Left Ventricular Endomyocardial Biopsy in Dilated Cardiomyopathy
- Retrospective cohort study
- longitudinal
Authors' conclusion
Left ventricular EMB is a safe diagnostic procedure. The extent of CVF in LV-EMB provides prognostic information in patients with DCM in addition to existing measures of left ventricular ejection fraction or NT-proBNP.
Study context
- Population
- Patients with suspected non-ischaemic dilated cardiomyopathies (DCM) undergoing LV endomyocardial biopsy as part of clinical work-up
- Participants
- 524 patients
- Exposure
- Left ventricular collagen volume fraction (LV-CVF) >32% vs LV-CVF ≤32%
- Outcome
- Composite of:
- HF-related death
- SCD
- Aborted SCD (appropriate ICD shock, sustained VT or CPR) or cardiac transplantation
- All-cause mortality
- Follow-up
- Median 43.2 months
Main finding
As reported in the abstract
Composite endpoint · median 43.2 months (2084 patient-years)
LV-CVF >32%
48
events
LV-CVF ≤32%
14
events
P < 0.0001
Observational data: associations, not effects.
Further findings
events
| Outcome | LV-CVF >32% | LV-CVF ≤32% | P value |
|---|---|---|---|
| All-cause mortality | 38 | 17 | P = 0.009 |
- All-cause mortality: 62 deaths in total
Independent predictors of unfavourable outcome (multivariable)
- LV-CVF and NT-proBNP independent predictors; HR
- 2.03 (95% CI 1.32-3.11)
Safety
Left ventricular EMB (LV-EMB) complications
- Major complications
- 0.76%
- Minor complications
- 2.1%
- Deaths due to endomyocardial biopsy (EMB)
- 0
Original publication
Safety and Prognostic Value of Left Ventricular Endomyocardial Biopsy in Dilated Cardiomyopathy. Eur J Heart Fail. Published 19 September 2025. doi:10.1002/ejhf.70019
Summarised from the published abstract; every number is checked against it